Pacific Biometrics Chief Medical Officer Dr. Mario Ehlers to Present Two Abstracts at the International Diabetes Federation "World Diabetes Congress Conference" Held December 3 - 7 in Cape Town, South Africa.

SEATTLE -- Mario Ehlers, M.D., Ph.D., the Chief Medical Officer of Pacific Biometrics, Inc. (OTCBB:PBME) ("PBI"), will present two abstracts at the International Diabetes Federation (IDF) "World Diabetes Congress Conference". The conference takes place December 3-7 and will be held at the Cape Town International Convention Centre. Dr. Ehlers will present two abstracts: "Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes" and "Subcutaneous Recombinant Glucagon-like Peptide-1 (rGLP-1) Reduces Food Intake in Obese Subjects".

The International Diabetes Federation (IDF) is the global advocate for the more than 200 million people with diabetes worldwide and represents 197 Diabetes Associations in 157 countries. IDF seeks to promote diabetes care, prevention and a cure worldwide. IDF is a non-governmental organization in official relations with the World Health Organization (WHO). The event will attract the highest level of international expertise in diabetes, provide a platform for discussion of the latest scientific advances in the field, and offer practical information on diabetes care, advocacy and awareness.

"Diabetes, metabolic syndrome and obesity-related morbidity have reached epidemic proportions in the industrialized world, and are rapidly increasing in the developing world as well," commented Dr. Ehlers. "These diseases have become a major focus for the biopharmaceutical industry, and represent one of PBI's special areas of expertise. We are pleased to provide lab testing to support clinical drug development for multiple sponsors in this area. The presentation at this major international conference will allow us to further raise our profile in this therapeutic area."

For more information about the conference, please visit www.idf2006.org

About Pacific Biometrics, Inc.

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, and through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies.

Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell viability technology to distinguish live from dead cells in a broad range of diagnostic applications.

For more information, visit the Company Web site at www.pacbio.com.